Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: A retrospective study by the EBMT LWP
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
Abstract
Adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis. Experience with allo-SCT for ATL appears encouraging but is limited to Japanese series. This retrospective analysis of the EBMT registry revealed 21 HTLV-I seropositive ATL including 7 acute and 12 lymphoma subtypes. Four patients received auto-SCT and rapidly died from ATL. Out of 17 allo-SCT (4 myeloablative, 13 reduced intensity), 6 are still alive (4 were in CR1 at SCT). Eleven patients died within 2 years, eight from relapse/progression and three from transplant toxicity. Six of seven informative patients who lived >12 months had chronic GVHD. Overall these results indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, supporting the existence of graft vs ATL effect also in non-Japanese patients. © 2014 Macmillan Publishers Limited. All rights reserved.
Description
Keywords
Adult, Aged, Disease progression, Female, Human t-lymphotropic virus 1, Humans, Leukemia-lymphoma, adult t-cell, Male, Middle aged, Prognosis, Retrospective studies, Treatment outcome, Alemtuzumab, Antivirus agent, Bortezomib, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Etoposide, Prednisone, Vincristine, Acute graft versus host disease, Allogeneic hematopoietic stem cell transplantation, Article, Autologous hematopoietic stem cell transplantation, Cancer registry, Chronic graft versus host disease, Clinical article, Clinical effectiveness, Disease association, Graft infection, Graft survival, Graft versus leukemia effect, Hematopoietic stem cell transplantation, Human, Leukemia relapse, Myeloablative conditioning, Outcome assessment, Priority journal, Reduced intensity conditioning, Retrospective study, Survival time, T cell lymphoma, Disease course, Human t cell leukemia virus 1